CD274 and gastric cancer: However, the known PD‐L1, MSI, EBV status, and TMB remain unstable in predicting the benefit of ICI therapy.[16, 21] To date, effective biomarkers to predict the responsiveness to neoadjuvant ICI therapy before treatment have remained absent, particularly in GC.